MUK Nine b: OPTIMUM Treatment Protocol
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
- Status
- COMPLETED
- Phase
- PHASE3
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Daratumumab in Treatment of PGNMID and C3 GN
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
- Status
- COMPLETED
- Phase
- PHASE2
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
- Status
- UNKNOWN
- Phase
- PHASE1
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
- Status
- COMPLETED
- Phase
- PHASE2